The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.